Astellas Balks On Vibativ License, But Focus Shifts To Tivozanib And MDV3100
This article was originally published in PharmAsia News
Executive Summary
Astellas terminates Vibativ license after just one year on the market to allocate resources for urology and transplantation while focus shifts to Phase III oncology drugs.
You may also be interested in...
Aveo/Astellas’ Tivozanib Bests Nexavar, Barely, In Advanced Kidney Cancer
Aveo/Astellas’ triple VEGF inhibitor tivozanib hit its progression-free survival endpoint of superiority over Onyx/Bayer’s Nexavar (sorafenib), but the question remains whether a three-month PFS advantage can confer first-line market superiority.
FCPA In The China Framework Warrants Special Attention
The US Department of Justice, SEC and the Chinese government have all increased investigations of corrupt practices, and incriminating evidence is easier than ever to find. What can companies do to protect themselves?
Astellas Regains Japan Losses With Xtandi Expansion
Astellas’ geographic and indication expansion strategy for Xtandi matches patent losses in Japan.